Answers are grounded in this paper and cite their sources.
Cisplatin is a first-line platinum-based chemotherapeutic agent that is widely implemented for the clinical management of diverse solid tumors, ranging from testicular and ovarian carcinoma to bladder and lung cancers. Nevertheless, its therapeutic benefits are substantially hampered by dose-limiting adverse effects such as nephrotoxicity and irreversible ototoxicity, as well as frequent intrinsic and acquired tumor multidrug resistance that greatly reduces treatment response. This article first outlines the core physicochemical and pharmacological features of cisplatin and further elaborates on the molecular mechanisms underlying cisplatin-related toxic injuries and multifaceted tumor resistance, including impaired drug uptake via cation transporters, enhanced intracellular detoxification, abnormal DNA damage repair, and the immunosuppressive tumor microenvironment. Moreover, it systematically summarizes recent research advances in formulation optimization and diverse nanovehicle delivery strategies, ranging from platinum(IV) prodrugs, passive- and active-targeted nanocarriers to stimulus-responsive and synergistic co-delivery platforms that can simultaneously load cisplatin and functional adjuvants. Finally, this review explores major translational obstacles in practical clinical application and puts forward prospective future research directions for cisplatin-based antitumor therapy.
No takes yet. Share an insight, caveat, or question.
Yuhui Tian (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: